GlassScriptPhysician profile
Eliot M Wallack
NPI 1750385449
$6,164.67
in general payments reported to CMS, 2019-2025
30 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $450 · 2021: $2,240 · 2022: $674 · 2023: $1,805 · 2024: $418 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223 · Consulting Fee: $175 · Education: $12.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.04 |
| Consulting Fee | $175.00 |
| Education | $12.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,532.83 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $865.87 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Teva Pharmaceuticals USA, INC. | $753.76 | 2019-2023 | Austedo Xr, Austedo |
| Emd Serono, INC. | $428.43 | 2019-2025 | Mavenclad |
| Pfizer INC. | $356.44 | 2023-2024 | |
| Genentech USA, INC. | $316.51 | 2021-2024 | Ocrevus, Enspryng |
| Lilly USA, LLC | $246.48 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $213.01 | 2022 | |
| Ucb, INC. | $204.96 | 2021-2024 | Nayzilam, Briviact |
| Neurelis, INC. | $152.39 | 2020-2023 | Valtoco |
| Scilex Pharmaceuticals INC. | $140.96 | 2022-2024 | Ztlido |
| Alexion Pharmaceuticals, INC. | $126.98 | 2019-2023 | Soliris |
| Amgen INC. | $126.73 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $119.37 | 2021 | |
| Sk Life Science, INC. | $105.51 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $97.29 | 2019-2023 | |
| Eisai INC. | $59.85 | 2022-2024 | |
| Impel Pharmaceuticals INC. | $46.13 | 2023 | Trudhesa |
| E.R. Squibb & Sons, L.L.C. | $40.21 | 2020 | |
| Celgene Corporation | $39.94 | 2021-2023 | Zeposia |
| Neurocrine Biosciences, INC. | $38.69 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $30.99 | 2023-2024 | Hyqvia, Gammagard |
| Vertical Pharmaceuticals, LLC | $23.30 | 2020 | |
| Ge Healthcare | $15.95 | 2019 | |
| Boston Scientific Corporation | $15.83 | 2022 | |
| Banner Life Sciences, LLC | $14.49 | 2022 | |
| Averitas Pharma INC. | $14.20 | 2023 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $13.56 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.88 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliot Wallack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.